A replicon RNA vaccine induces durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned — BiorXiv

Aug 9, 2022 | Publications

Click here to view...

HDT Bio Awarded $1.8M U.S. Army Grant to Develop Antiviral Nasal Spray to Protect Military Personnel from a Broad Spectrum of Deadly Viruses

Aug 8, 2022 | Press Releases

The antiviral product, HDT-201, will utilize company’s RNA/LION™ platform technology and ultimately will be available to the public. SEATTLE, WA (August 8, 2022) – HDT Bio Corp., a developer of immunotherapies for infectious diseases and oncology, announced today it...

Public Library of Science: And Then There Were 33…The Latest 11 COVID Vaccines to Reach the Phase 3 Results Milestone

Aug 5, 2022 | In the News

Click here to view...

Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge. — EBioMedicine

Jul 27, 2022 | Publications

Click here to view...

HDT Bio Awarded $1.5M Phase 2 NIH SBIR Grant to Develop RNA Vaccines and Therapeutics for Enterovirus D68, a Respiratory Virus Causing Severe Neurological Conditions in Children

Jul 20, 2022 | Press Releases

SEATTLE, WA (July 20, 2022) – HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today it has been awarded a nearly $1.5M Phase 2 Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and...